Maxcyte Inc (MXCT)

$2.88 +0.04 (1.41%)
Market Cap 306.18M
Revenue (ttm) 38.63M
Net Income (ttm) -41.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -106.29%
Debt to Equity Ratio 0.00
Volume 289,800
Avg Vol 672,832
Day's Range N/A - N/A
Shares Out 106.31M
Stochastic %K 98%
Beta 1.39
Analysts Strong Sell
Price Target $7.33

Latest News on MXCT

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 10, 2025, 2:00 AM EDT - 18 days ago

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

Mar 15, 2025, 8:30 AM EDT - 6 weeks ago

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:52 PM EDT - 6 weeks ago

MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

Mar 11, 2025, 4:05 PM EDT - 6 weeks ago

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Feb 12, 2025, 2:00 AM EST - 2 months ago

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Feb 7, 2025, 2:00 AM EST - 2 months ago

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Jan 30, 2025, 10:36 AM EST - 3 months ago

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Jan 30, 2025, 2:00 AM EST - 3 months ago

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 3:05 AM EST - 3 months ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte Announces Retirement of Board Member Art Mandell

Dec 23, 2024, 2:00 AM EST - 4 months ago

MaxCyte Announces Retirement of Board Member Art Mandell

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Dec 9, 2024, 2:00 AM EST - 5 months ago

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Nov 13, 2024, 8:05 AM EST - 5 months ago

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:01 PM EST - 6 months ago

MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

Nov 6, 2024, 4:05 PM EST - 6 months ago

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

MaxCyte to Participate in Two Upcoming Investor Conferences

Oct 31, 2024, 8:05 AM EDT - 6 months ago

MaxCyte to Participate in Two Upcoming Investor Conferences

MaxCyte Appoints Cynthia Collins to its Board of Directors

Oct 15, 2024, 8:05 AM EDT - 6 months ago

MaxCyte Appoints Cynthia Collins to its Board of Directors

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 11, 2024, 8:05 AM EDT - 7 months ago

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Oct 10, 2024, 8:05 AM EDT - 7 months ago

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

Oct 4, 2024, 5:19 PM EDT - 7 months ago

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

Sep 16, 2024, 2:00 AM EDT - 8 months ago

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

Sep 5, 2024, 4:05 PM EDT - 8 months ago

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 12:09 AM EDT - 9 months ago

MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

Aug 6, 2024, 4:05 PM EDT - 9 months ago

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 9, 2024, 4:05 PM EDT - 10 months ago

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

May 29, 2024, 8:05 AM EDT - 11 months ago

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 22, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

May 11, 2024, 8:35 AM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

May 7, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 10, 2024, 8:05 AM EDT - 1 year ago

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Apr 2, 2024, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:40 PM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Mar 12, 2024, 4:05 PM EDT - 1 year ago

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

Mar 4, 2024, 4:05 PM EST - 1 year ago

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

Feb 9, 2024, 8:05 AM EST - 1 year ago

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Jan 30, 2024, 8:05 AM EST - 1 year ago

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Jan 23, 2024, 8:05 AM EST - 1 year ago

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

Jan 8, 2024, 4:05 PM EST - 1 year ago

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

Jan 3, 2024, 8:05 AM EST - 1 year ago

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

Jan 2, 2024, 2:00 AM EST - 1 year ago

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

Dec 11, 2023, 4:05 PM EST - 1 year ago

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

MaxCyte May Benefit From Potential Gene Therapy Approval

Nov 27, 2023, 8:00 AM EST - 1 year ago

MaxCyte May Benefit From Potential Gene Therapy Approval

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

Nov 16, 2023, 8:05 AM EST - 1 year ago

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 11:06 PM EST - 1 year ago

MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

Nov 8, 2023, 4:05 PM EST - 1 year ago

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

Oct 4, 2023, 4:05 PM EDT - 1 year ago

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

Sep 6, 2023, 8:05 AM EDT - 1 year ago

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

MaxCyte to Participate in Baird Global Healthcare Conference

Sep 5, 2023, 8:05 AM EDT - 1 year ago

MaxCyte to Participate in Baird Global Healthcare Conference

MaxCyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 10:13 PM EDT - 1 year ago

MaxCyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

Aug 9, 2023, 4:05 PM EDT - 1 year ago

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

Aug 1, 2023, 8:05 AM EDT - 1 year ago

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients